On page 3372, last paragraph of "Results" section should read from "In Severe Group, patients who were able to continue nintedanib for more than 3 months (n = 4) exhibited significantly better prognosis compared to those who could not (n = 13) (P = 0.007) ( Figure 6 )." to "In Severe Group, patients who were able to con tinue nintedanib for more than 3 months (n = 13) exhibited significantly better prognosis compared to those who could not (n = 4) (P = 0.007) ( Figure 6 )."
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